Gossamer Bio Investors Face Lead Plaintiff Deadline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy GOSS?
Source: Globenewswire
- Severe Investor Losses: Gossamer Bio's shares plummeted over 80% on February 23, 2026, dropping from $2.13 to $0.42 after the Phase 3 PROSERA study failed to meet its primary endpoint, resulting in significant financial losses for investors and damaging the company's reputation and future financing capabilities.
- Lead Plaintiff Application Deadline: Investors must file a motion by June 1, 2026, to seek lead plaintiff status; those who miss this deadline can still participate as absent class members in any recovery, ensuring their rights are preserved without additional action.
- Role of Lead Plaintiff: The lead plaintiff is typically the applicant with the largest financial stake, responsible for selecting counsel and directing the litigation, which is particularly crucial in the Gossamer case where selecting an engaged lead plaintiff is vital for representing shareholder interests effectively.
- Overview of Litigation Process: After the deadline, the court will review all lead plaintiff applications and appoint the most suitable representative, with the entire litigation process expected to take two to four years to resolve, requiring investors to prepare relevant documentation to support their claims.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.368
Low
10.00
Averages
12.33
High
15.00
Current: 0.368
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Filed Against Gossamer Bio for Securities Fraud
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Gossamer Bio in the Southern District of California on behalf of investors who purchased securities between June 16, 2025, and February 20, 2026, with a deadline of June 1, 2026, to apply as lead plaintiff.
- False Information Allegations: The lawsuit alleges that Gossamer provided misleading information regarding its Phase 3 PROSERA study while concealing adverse facts about the trial design, particularly concerning the placebo response, leading shareholders to buy securities at artificially inflated prices.
- Investor Losses: Due to Gossamer's false statements, investors purchased shares at inflated prices, resulting in potential financial losses, highlighting significant deficiencies in the company's transparency and compliance practices.
- Legal Consultation Opportunity: Bragar Eagel & Squire offers no-cost legal consultations, encouraging affected investors to contact the firm to understand their legal rights and potential claims, demonstrating a commitment to protecting investor interests.
See More
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action lawsuit for failing to disclose the true conditions of Latin American patients, resulting in its Phase 3 PROSERA study not meeting primary endpoints, with a lead plaintiff deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy & Digital (NASDAQ:NUAI) is being sued for overstating progress on its Texas data center project and involvement in fraudulent activities, with investors needing to file by June 1, 2026, facing risks of misleading financial results.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is accused of overselling its projected book-to-bill ratio for Q4 2025, with a lead plaintiff deadline of June 5, 2026, potentially indicating a weak business environment.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses in these companies to contact their firm to understand their legal rights and ensure protection in the class actions.
See More
Gossamer Bio Faces Class Action Lawsuit Following Trial Failure
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ: GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, covering the period from June 16, 2025, to February 20, 2026, which has led to significant investor losses.
- Stock Price Plunge: Following the trial failure announcement, Gossamer's stock price plummeted by 80%, reflecting not only the market's pessimistic outlook on its future prospects but also prompting investigations by shareholder rights firms like Hagens Berman for potential violations of federal securities laws.
- Trial Design Controversy: The lawsuit focuses on Gossamer's disclosures regarding the PROSERA trial design, including patient recruitment protocols and site monitoring, alleging that the company misled investors by assuring them of positive outcomes despite being aware of design issues.
- Nasdaq Compliance Risk: On April 9, 2026, Gossamer revealed that it had not met the minimum bid price of $1 required for continued listing on the Nasdaq Global Select Market since February 24, 2026, further exacerbating investor concerns regarding the company's compliance and future viability.
See More
Faruqi & Faruqi Investigates Gossamer Bio Investor Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating Gossamer Bio, Inc. for potential claims related to securities purchased between June 16, 2025, and February 20, 2026, indicating possible legal risks for the company.
- Claims Deadline: Investors must contact Faruq & Faruq by June 1, 2026, to seek lead plaintiff status in a federal securities class action, which could significantly impact their legal options and rights.
- Investor Rights Protection: Partner Josh Wilson encourages affected investors to reach out directly to discuss their legal rights, demonstrating a commitment to protecting investor interests.
- Market Reaction Anticipation: The initiation of the legal investigation may negatively impact Gossamer's stock price, prompting investors to closely monitor developments to assess potential risks.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 16, 2025, and February 20, 2026.
- False Statement Allegations: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning placebo response controls at certain testing sites, rendering its public statements false and materially misleading throughout the class period.
- Investor Losses: Following the revelation of the truth about Gossamer, investors suffered damages, and the Schall Law Firm encourages affected investors to contact them before June 1, 2026, to participate in the lawsuit.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, allowing investors to reach out via phone or website to understand their rights and decide whether to join the class action.
See More
Class Action Lawsuit Announced for Gossamer Bio Investors
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of Gossamer Bio, Inc. (NASDAQ:GOSS) investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential investor losses due to misleading information.
- Compensation Structure: Investors participating in the lawsuit may be entitled to compensation without any upfront costs, highlighting a risk-free legal support mechanism for affected parties.
- Counsel Selection Importance: The firm emphasizes the necessity of choosing qualified legal counsel with a proven track record, showcasing its expertise and success in securities class actions, which can significantly impact the outcome for investors.
- Case Details Unveiled: The lawsuit alleges that Gossamer provided misleading statements regarding its Phase 3 PROSERA study, resulting in investor damages when the true information became public, underscoring serious transparency issues within the company.
See More
Class Action Filed Against Gossamer Bio for Securities Fraud
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Gossamer Bio in the Southern District of California on behalf of investors who purchased securities between June 16, 2025, and February 20, 2026, with a deadline of June 1, 2026, to apply as lead plaintiff.
- False Information Allegations: The lawsuit alleges that Gossamer provided misleading information regarding its Phase 3 PROSERA study while concealing adverse facts about the trial design, particularly concerning the placebo response, leading shareholders to buy securities at artificially inflated prices.
- Investor Losses: Due to Gossamer's false statements, investors purchased shares at inflated prices, resulting in potential financial losses, highlighting significant deficiencies in the company's transparency and compliance practices.
- Legal Consultation Opportunity: Bragar Eagel & Squire offers no-cost legal consultations, encouraging affected investors to contact the firm to understand their legal rights and potential claims, demonstrating a commitment to protecting investor interests.
See More
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action lawsuit for failing to disclose the true conditions of Latin American patients, resulting in its Phase 3 PROSERA study not meeting primary endpoints, with a lead plaintiff deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy & Digital (NASDAQ:NUAI) is being sued for overstating progress on its Texas data center project and involvement in fraudulent activities, with investors needing to file by June 1, 2026, facing risks of misleading financial results.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is accused of overselling its projected book-to-bill ratio for Q4 2025, with a lead plaintiff deadline of June 5, 2026, potentially indicating a weak business environment.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses in these companies to contact their firm to understand their legal rights and ensure protection in the class actions.
See More
Gossamer Bio Faces Class Action Lawsuit Following Trial Failure
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ: GOSS) is facing a securities class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, covering the period from June 16, 2025, to February 20, 2026, which has led to significant investor losses.
- Stock Price Plunge: Following the trial failure announcement, Gossamer's stock price plummeted by 80%, reflecting not only the market's pessimistic outlook on its future prospects but also prompting investigations by shareholder rights firms like Hagens Berman for potential violations of federal securities laws.
- Trial Design Controversy: The lawsuit focuses on Gossamer's disclosures regarding the PROSERA trial design, including patient recruitment protocols and site monitoring, alleging that the company misled investors by assuring them of positive outcomes despite being aware of design issues.
- Nasdaq Compliance Risk: On April 9, 2026, Gossamer revealed that it had not met the minimum bid price of $1 required for continued listing on the Nasdaq Global Select Market since February 24, 2026, further exacerbating investor concerns regarding the company's compliance and future viability.
See More
Faruqi & Faruqi Investigates Gossamer Bio Investor Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating Gossamer Bio, Inc. for potential claims related to securities purchased between June 16, 2025, and February 20, 2026, indicating possible legal risks for the company.
- Claims Deadline: Investors must contact Faruq & Faruq by June 1, 2026, to seek lead plaintiff status in a federal securities class action, which could significantly impact their legal options and rights.
- Investor Rights Protection: Partner Josh Wilson encourages affected investors to reach out directly to discuss their legal rights, demonstrating a commitment to protecting investor interests.
- Market Reaction Anticipation: The initiation of the legal investigation may negatively impact Gossamer's stock price, prompting investors to closely monitor developments to assess potential risks.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 16, 2025, and February 20, 2026.
- False Statement Allegations: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning placebo response controls at certain testing sites, rendering its public statements false and materially misleading throughout the class period.
- Investor Losses: Following the revelation of the truth about Gossamer, investors suffered damages, and the Schall Law Firm encourages affected investors to contact them before June 1, 2026, to participate in the lawsuit.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, allowing investors to reach out via phone or website to understand their rights and decide whether to join the class action.
See More
Class Action Lawsuit Announced for Gossamer Bio Investors
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of Gossamer Bio, Inc. (NASDAQ:GOSS) investors who purchased securities between June 16, 2025, and February 20, 2026, indicating potential investor losses due to misleading information.
- Compensation Structure: Investors participating in the lawsuit may be entitled to compensation without any upfront costs, highlighting a risk-free legal support mechanism for affected parties.
- Counsel Selection Importance: The firm emphasizes the necessity of choosing qualified legal counsel with a proven track record, showcasing its expertise and success in securities class actions, which can significantly impact the outcome for investors.
- Case Details Unveiled: The lawsuit alleges that Gossamer provided misleading statements regarding its Phase 3 PROSERA study, resulting in investor damages when the true information became public, underscoring serious transparency issues within the company.
See More
